Browse TEK

Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein. Cell junction Cell junction, focal adhesion Cytoplasm, cytoskeleton. Secreted Note=Recruited to cell-cell contacts in quiescent endothelial cells (PubMed:18425120, PubMed:18425119). Colocalizes with the actin cytoskeleton and at actin stress fibers during cell spreading. Recruited to the lower surface of migrating cells, especially the rear end of the cell. Proteolytic processing gives rise to a soluble extracellular domain that is secreted (PubMed:11806244).
Domain PF00041 Fibronectin type III domain
PF10430 Tie-2 Ig-like domain 1
PF07714 Protein tyrosine kinase
Function

Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001525 angiogenesis
GO:0001666 response to hypoxia
GO:0001667 ameboidal-type cell migration
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0001952 regulation of cell-matrix adhesion
GO:0001954 positive regulation of cell-matrix adhesion
GO:0001958 endochondral ossification
GO:0002040 sprouting angiogenesis
GO:0003007 heart morphogenesis
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0006644 phospholipid metabolic process
GO:0007044 cell-substrate junction assembly
GO:0007045 cell-substrate adherens junction assembly
GO:0007160 cell-matrix adhesion
GO:0007163 establishment or maintenance of cell polarity
GO:0007507 heart development
GO:0008015 blood circulation
GO:0010594 regulation of endothelial cell migration
GO:0010595 positive regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0014074 response to purine-containing compound
GO:0016525 negative regulation of angiogenesis
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019216 regulation of lipid metabolic process
GO:0030335 positive regulation of cell migration
GO:0031348 negative regulation of defense response
GO:0031532 actin cytoskeleton reorganization
GO:0031589 cell-substrate adhesion
GO:0032102 negative regulation of response to external stimulus
GO:0032878 regulation of establishment or maintenance of cell polarity
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033674 positive regulation of kinase activity
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0034332 adherens junction organization
GO:0034333 adherens junction assembly
GO:0034446 substrate adhesion-dependent cell spreading
GO:0036075 replacement ossification
GO:0036293 response to decreased oxygen levels
GO:0040017 positive regulation of locomotion
GO:0043114 regulation of vascular permeability
GO:0043410 positive regulation of MAPK cascade
GO:0043434 response to peptide hormone
GO:0043491 protein kinase B signaling
GO:0043542 endothelial cell migration
GO:0043550 regulation of lipid kinase activity
GO:0043551 regulation of phosphatidylinositol 3-kinase activity
GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity
GO:0043627 response to estrogen
GO:0044089 positive regulation of cellular component biogenesis
GO:0045216 cell-cell junction organization
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045785 positive regulation of cell adhesion
GO:0045834 positive regulation of lipid metabolic process
GO:0046683 response to organophosphorus
GO:0046777 protein autophosphorylation
GO:0048014 Tie signaling pathway
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048041 focal adhesion assembly
GO:0048514 blood vessel morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050900 leukocyte migration
GO:0051259 protein oligomerization
GO:0051272 positive regulation of cellular component movement
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051591 response to cAMP
GO:0051893 regulation of focal adhesion assembly
GO:0051894 positive regulation of focal adhesion assembly
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0060216 definitive hemopoiesis
GO:0060343 trabecula formation
GO:0060347 heart trabecula formation
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060350 endochondral bone morphogenesis
GO:0061383 trabecula morphogenesis
GO:0061384 heart trabecula morphogenesis
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070482 response to oxygen levels
GO:0072577 endothelial cell apoptotic process
GO:0090109 regulation of cell-substrate junction assembly
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090218 positive regulation of lipid kinase activity
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1901652 response to peptide
GO:1901888 regulation of cell junction assembly
GO:1901890 positive regulation of cell junction assembly
GO:1903391 regulation of adherens junction organization
GO:1903393 positive regulation of adherens junction organization
GO:1903725 regulation of phospholipid metabolic process
GO:1903727 positive regulation of phospholipid metabolic process
GO:1904018 positive regulation of vasculature development
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:2000147 positive regulation of cell motility
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2000249 regulation of actin cytoskeleton reorganization
GO:2000251 positive regulation of actin cytoskeleton reorganization
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
Cellular Component GO:0001725 stress fiber
GO:0005884 actin filament
GO:0005902 microvillus
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0009925 basal plasma membrane
GO:0015629 actin cytoskeleton
GO:0016323 basolateral plasma membrane
GO:0016324 apical plasma membrane
GO:0030055 cell-substrate junction
GO:0032432 actin filament bundle
GO:0042641 actomyosin
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0045178 basal part of cell
GO:0097517 contractile actin filament bundle
GO:0098589 membrane region
GO:0098857 membrane microdomain
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04151 PI3K-Akt signaling pathway
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-210993: Tie2 Signaling
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TEK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TEK and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23649001Breast CarcinomaInhibit immunityTEMs from breast tumors are able to suppress tumor-specific immune responses. Importantly, proangiogenic and suppressive functions of TEMs are similarly driven by TIE-2 and VEGFR kinase activity.
Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TEK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TEK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3390.232
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3620.559
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3170.491
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.030.939
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3780.834
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4010.846
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.380.421
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7070.491
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0280.981
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9540.403
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.4130.096
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3270.0113
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TEK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TEK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TEK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TEK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TEK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TEK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TEK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTEK
NameTEK tyrosine kinase, endothelial
Aliases TIE2; TIE-2; VMCM1; CD202b; VMCM; venous malformations, multiple cutaneous and mucosal; endothelial tyrosine ......
Chromosomal Location9p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TEK collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TEK.
ID Name Drug Type Targets #Targets
DB00415AmpicillinSmall MoleculeSLC15A1, SLC15A2, TEK3
DB05294VandetanibSmall MoleculeEGFR, PTK6, RET, TEK, VEGFA5
DB08221N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDESmall MoleculeTEK1
DB08896RegorafenibSmall MoleculeABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, ......18
DB08901PonatinibSmall MoleculeABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, P ......15